Coeurative, Inc. is a privately owned pharmaceutical development company incorporated in Delaware and operating in Virginia. The company was formed to create and develop curative strategies for the management of cardiovascular and cardiopulmonary diseases associated with cellular hypoxia. The patented compounds developed by COEURative generate nitric oxide, a vasodilator and modulator of inflammation, in the lining of blood vessels. These same compounds should also have specific anti-viral activity against the virus responsible for COVID-19.
Cellular hypoxia can be defined as a lack of oxygen at the level of individual cells, not necessarily related to a lack of oxygen at the level of a whole organism or an environment. Most cardiovascular diseases involve a deficiency of oxygen delivery to cells (cellular hypoxia.) COEURative is developing a new class of pharmaceuticals based on twenty-five years of research on the regulation of hypoxia-mediated events in blood vessels. The market for products that facilitate long-term management of these conditions will grow along with the population of patients that will benefit from pharmaceuticals. A successful compound should generate an average of $2 billion a year for ten years following ten years of development.
Heart and blood vessel diseases remain the leading causes of death in the developed world. There are still substantial opportunities for clinical development of small molecule compounds for treatment and prevention. Health care providers point with some pride to the substantial decreases in the death rate due to cardiovascular diseases. The truth is that our success has created a new population of patients: people who used to die of these diseases are now becoming chronic patients in need of long term management. Cardiovascular diseases are growing in prevalence and will continue to be the most significant public health challenge.
The COVID-19 pandemic also calls for new therapeutics. Hypoxia is one of the classic signs of COVID-19. Myocardial injury (due to local inflammation and cardiac hypoxia) is strongly correlated with fatal outcomes in COVID-19. Nitric oxide donor compounds inhibit SARS-coronavirus infection in vitro. The patented COEURative compounds induce formation of nitric oxide and are proposed as novel anti-viral agents for treatment of COVID-19.
There are three proposed indications for these compounds.
The first indication is as an antianginal agent. The compounds are expected to improve exercise capacity in the setting of local hypoxia and coronary artery disease with the drugs acting as coronary vasodilators through augmented release of endothelial nitric oxide.
The second indication is for secondary prevention of major adverse events associated with endothelial hypoxia in cardiovascular diseases. Vasodilatation is sought as well as ischemic preconditioning and modulation of vascular inflammatory mediators via the augmented release of endothelial nitric oxide.
The third and latest indication is as an anti-viral agent with particular effect on COVID-19 virus (SARS-CoV-2.) Direct anti-viral activity is expected as well as an anti-viral effect from targeted nitric oxide release.
Proof of mechanism studies are underway.
Patent No. US 10,501,471 titled “COMPOUNDS USEFUL FOR TREATING CARDIOVASCULAR DISEASES” was issued on December 10, 2019. Patent No. US 10,913,748 was issued as a continuation patent on February 9, 2021. Recently our filing with the World Intellectual Property Organization was published: PCT – US 2019 058241. Nonprovisional US Patent Application 17,211,778 and International Patent Application PCT/US21/24540 are pending,
PLEASE USE THIS FORM FOR CORRESPONDENCE:
John F. Schmedtje Jr., MD
President and CEO
201 McClanahan Street SW
Roanoke, VA 24014
This document is not an offer or agreement to buy or sell securities, or a solicitation of an offer to buy or sell securities. Any such offering or agreement will be made, if at all, pursuant to definitive subscription or other offering materials.